Jnana Therapeutics

What Jnana Therapeutics does

Jnana Therapeutics is a Boston-based clinical-stage biotechnology company founded in 2017 that developed the RAPID (Reactive Affinity Probe Interaction Discovery) chemoproteomics platform for small molecule drug discovery. The platform uses proprietary Reactive Affinity Probes (RAPs) to identify binding sites on validated protein targets in living cells and supports drug discovery against historically challenging target classes including SLC transporters, transcription factors, signaling scaffold proteins, phosphatases, GPCRs, and helicases. The company's lead clinical asset is JNT-517 (repinatrabit), a first-in-class oral allosteric inhibitor of the SLC6A19 phenylalanine transporter in development for phenylketonuria (PKU), a rare inherited metabolic disease affecting approximately 1 in 24,000 individuals globally.

The company's pre-revenue business model was built on milestone payments from pharmaceutical partnerships, including two collaboration agreements with Roche signed in July 2020 and December 2022 spanning immune-mediated, neurological, and oncology indications, plus a collaboration with Neurocrine Biosciences. In September 2024, Jnana was acquired by Otsuka Pharmaceutical Co., Ltd. for $800 million upfront plus up to $325 million in development and regulatory milestones, becoming a wholly owned subsidiary. Post-acquisition, Otsuka assumed sponsorship of the global Phase 3 PheORD trial for repinatrabit initiated in December 2025 (with primary endpoint completion anticipated in late 2026) and will manage global commercialization through its pharmaceutical commercial organization upon potential approval. Jnana continues to operate as an Otsuka subsidiary advancing the lead PKU program and a broader pipeline in immune-mediated diseases, including IRF3 and protein-protein interaction targets.

Name

Jnana Therapeutics

Legal name

Jnana Therapeutics Inc.

Website

https://jnanatx.com

Company type

Private

Founded year

2017

Operating status

Acquired

Headcount range

51–100 employees

Short description

Jnana Therapeutics is a Boston-based clinical-stage biotechnology company, now a wholly owned Otsuka subsidiary, that uses its proprietary RAPID chemoproteomics platform to develop small molecule therapies, with lead candidate repinatrabit in Phase 3 for phenylketonuria (PKU).

Ownership category

akta.pro rank

Product category

Small Molecule Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

akta.pro secondary industries

Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH), In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK)

Keywords

• Small molecule therapeutics
• Chemoproteomics drug discovery
• Rare disease therapies
• Allosteric inhibitors
• PKU treatment

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Drug Development and Licensing: Pre-revenue clinical-stage biotechnology company. Revenue will be generated through potential future product sales (if drugs are approved) and through milestone payments from partnership agreements with pharmaceutical companies. Acquired by Otsuka Pharmaceutical in September 2024.
2. Partnership and Collaboration Agreements: Revenue generated through milestone payments and potential royalties from collaboration agreements with Roche and Neurocrine Biosciences for drug discovery and development programs.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Jnana Therapeutics is a clinical-stage biotechnology company that develops first-in-class small molecule medicines using its proprietary RAPID (Reactive Affinity Probe Interaction Discovery) chemoproteomics platform. Its lead drug candidate is JNT-517 (repinatrabit), an oral allosteric inhibitor of the SLC6A19 phenylalanine transporter being advanced for the treatment of phenylketonuria (PKU). The company also pursues discovery programs in immune-mediated diseases, oncology, and neurological disorders, partly through collaboration agreements with Roche and Neurocrine Biosciences.

Product overview

Jnana Therapeutics is a clinical-stage biotechnology company that developed the RAPID (Reactive Affinity Probe Interaction Discovery) chemoproteomics platform for small molecule drug discovery. The company's lead product candidate is JNT-517 (now called repinatrabit), a first-in-class oral small molecule inhibitor targeting SLC6A19 for phenylketonuria (PKU) treatment. Jnana was acquired by Otsuka Pharmaceutical in September 2024 and operates as a wholly owned subsidiary, advancing programs in PKU and immune-mediated diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• RAPID Platform A next-generation chemoproteomics drug discovery platform that uses proprietary Reactive Affinity Probes (RAPs) to identify unique binding sites on validated protein targets in living cells, enabling discovery of small molecule medicines for challenging target classes including SLC transporters, transcription factors, signaling scaffold proteins, phosphatases, GPCRs, and helicases.
• JNT-517 (Repinatrabit) First-in-class oral small molecule allosteric inhibitor of the SLC6A19 phenylalanine transporter, being developed for the treatment of phenylketonuria (PKU) regardless of age or genetic background. Phase 1b/2 data demonstrated 60% mean reduction in blood phenylalanine levels at 150mg twice daily dose.
• Immune-Mediated Diseases Pipeline Discovery-stage small molecule programs targeting challenging immune-related targets including IRF3, STING pathway components, and undisclosed protein-protein interaction targets for autoimmune and inflammatory disorders. Some programs are advanced through partnerships with Roche and Neurocrine Biosciences.

Quantifiable outcome

• 60% mean reduction in blood phenylalanine levels at 150mg twice daily dose in Phase 1b/2 study (statistically significant, p<0.0002 vs placebo)
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• RochecoreStrategic or Co-development Partner · 1 July 2020First collaboration agreement signed in July 2020 to discover and develop novel small molecule medicines for immune-mediated and neurological diseases by targeting SLC metabolite transporters. In late 2022, a second collaboration and license agreement was entered to discover novel small molecule drugs directed to diverse target classes beyond the SLC family in cancer, immune-mediated and neurological diseases. Achievement of pre-clinical milestones triggers milestone payments to Jnana.
• Neurocrine BiosciencesminorStrategic or Co-development PartnerCollaboration for undisclosed partnered programs within Cancer, Immune-Mediated, and Neurological Diseases. Part of Jnana's broader strategy to leverage RAPID platform through partnerships.
• Otsuka PharmaceuticalcoreStrategic or Co-development PartnerAcquired Jnana Therapeutics in September 2024 for $800 million upfront plus up to $325 million in development and regulatory milestones. Jnana became a wholly owned subsidiary of Otsuka, with Otsuka handling Phase 3 development and commercialization of repinatrabit (JNT-517) and advancing the broader pipeline.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Vividion Therapeutics: Chemoproteomics-based small molecule discovery platform focused on previously undruggable targets; acquired by Bayer in 2021 — directly comparable to Jnana's RAPID platform approach and similar platform-plus-pipeline business model.
• BioMarin Pharmaceutical: Markets Kuvan (sapropterin) and Palynziq (pegvaliase) for phenylketonuria — the incumbent competitor against which repinatrabit will be commercially benchmarked.
• Scorpion Therapeutics: Precision oncology company using a chemoproteomics-style covalent screening platform to drug challenging oncogene targets — comparable in platform architecture and target-class ambition to Jnana's RAPID.
• Frontier Medicines: Chemoproteomics and covalent chemistry platform developing small molecules against previously undruggable disease targets — closely parallels Jnana's RAPID platform and target-class approach.
• Kymera Therapeutics: Targeted protein degradation (PROTAC) and chemoproteomics-enabled small molecule discovery company; comparable platform-plus-pipeline biotech at similar clinical-stage inflection.
• Homology Medicines: Develops gene therapy and editing approaches for rare genetic diseases including phenylketonuria — directly competing therapeutic modality for the same PKU patient population.
• Foghorn Therapeutics: Chromatin biology-focused small molecule platform tackling historically difficult oncology targets — comparable platform-based biotech developing first-in-class small molecules against challenging target classes.
• Maze Therapeutics: Genetic disease-focused biotechnology company using functional genomics to develop small molecule and genetic medicines — comparable in rare-disease pipeline focus and platform-enabled discovery approach.

Broad incumbents

• Recursion Pharmaceuticals: Tech-enabled drug discovery platform combining high-throughput biology with machine learning — broader incumbent in platform-driven small molecule discovery with overlapping pipeline ambitions.
• PTC Therapeutics: Established rare disease and small molecule therapeutics company with commercial infrastructure across metabolic and neurological rare diseases — comparable in rare-disease commercial focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/jnanatx
• LinkedInlinkedin.com/company/jnana-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jnana Therapeutics